drugset / Trial / NCT01374178
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy subjects. The study is approximately 12 weeks.
Timeline
- Start
- 2011-06
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2963016 | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |